Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-14
2006-11-14
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255030, C514S256000, C514S318000, C544S335000, C544S358000, C546S234000, C546S262000, C546S268100, C546S268700, C546S269100, C546S269100, C546S274700, C546S276400, C546S278100, C546S279100, C546S336000, C548S146000, C548S235000, C548S247000, C548S338100, C548S374100, C548S537000
Reexamination Certificate
active
07135472
ABSTRACT:
The present invention provides novel 3-heterocyclic benzylamides and related derivatives having the general Formula Iwherein R1, R2, R3, R4, R5, R6, A and Het are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said novel 3-heterocyclic benzylamides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.
REFERENCES:
patent: 4735959 (1988-04-01), Grell et al.
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 6046239 (2000-04-01), Lennox et al.
patent: RE37035 (2001-01-01), Grell et al.
patent: 6413995 (2002-07-01), Hasegawa et al.
patent: 6831080 (2004-12-01), Wu et al.
patent: 6900210 (2005-05-01), Wu et al.
patent: 810220 (1997-12-01), None
patent: 45-14291 (1970-05-01), None
patent: 2-138159 (1990-05-01), None
patent: WO 00/07993 (2000-02-01), None
patent: WO 00/42013 (2000-07-01), None
patent: WO 01/10380 (2001-02-01), None
patent: WO 01/10381 (2001-02-01), None
Gribkoff, V.K., “The therapeutic potential of neuronal KCNQ channel modulators”,Expert Opinions Ther. Targets(2003) 7(6) p. 737-748.
He Huan
L'Heureux Alexandre
Wu Yong-Jin
Algieri Aldo A.
Bristol--Myers Squibb Company
McKenzie Thomas
LandOfFree
3-Heterocyclic benzylamide derivatives as potassium channel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-Heterocyclic benzylamide derivatives as potassium channel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-Heterocyclic benzylamide derivatives as potassium channel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679921